A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines | NCT01749423 | Trialant
WithdrawnObservationalUpdated Feb 3, 2014
A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines
ClinicalTrials.gov ID
NCT01749423
Lead Sponsor
AllerganINDUSTRY
Overall Status
Withdrawn
Study Type
Observational
Enrollment
0Actual
Last Update Posted
Feb 3, 2014Estimated
Start Date
Nov 2012
Primary Completion Date
Dec 2013Estimated
Completion Date
Dec 2013Estimated
Brief Summary
This study will evaluate the effectiveness of OnabotulinumtoxinA to prevent headaches in patients with Chronic Migraine.
Chronic Migraine, Headache
OnabotulinumtoxinA
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
History of chronic migraines
15 or more headache days over a 30 day period
A minimum of 2 consecutive treatment cycles of 100 units onabotulinumtoxinA and a minimum of 2 consecutive treatment cycles with the onabotulinumtoxinA dosing between 155 and 195 units
Exclusion Criteria:
Any treatment cycle dose of onabotulinumtoxinA greater than 200 units